Bioelectronics Corp (BIEL)

[GetSeriousOK]

Just to highlight ONE point:

...that has demonstrated the ability to replace, reduce, or avoid opioid use or the quantity of opioids prescribed in a clinical trial or through data published in a peer-reviewed journal.

Currently, The ActiPatch device is currently missing that requirement. The hope and dream is that Ilfeld will publish his Pilot Study before the end of 2024 and the CMS will decide that this Pilot Study satisfies this requirement.

And regarding the "Utility Patent Application Filing:" the FACT remains that the company let all its other utility patents expire. The ActiPatch and RecoveryRx are currently NOT patent protected.

https://patentcenter.uspto.gov/applications/10384101

A patent for chronic Inflammation is better than nothing, and canine studies are better than nothing, but the lack of existing patent protection is dumbfounding.

And the hubris of bragging about a new patent application after letting all the other patents expire due to negligence is.... well, typical BIEL, I suppose.